Previous 10 | Next 10 |
Australian TGA Approval Decision Expected in Early 2020 ENGLEWOOD, CO / ACCESSWIRE / April 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the ...
ENGLEWOOD, CO / ACCESSWIRE / April 16, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the formal appointment of Steven Boyd, Founder and Chief Investme...
Reebonz Holding (NASDAQ: RBZ ) +89% . More news on: Reebonz Holding Limited, Castor Maritime Inc., China SXT Pharmaceuticals, Inc., Stocks on the move, Read more ...
Aytu BioScience (NASDAQ: AYTU ) is up 12% premarket on light volume on the heels of updated results from a post-market Phase 4 study assessing the effects of Natesto , a nasally administered testosterone replacement therapy, on sperm production. The data were presented at the ...
Interim Results Demonstrated Preservation of Sperm Parameters After Six Months of Treatment with Nasally-Administered Natesto Testosterone Gel Natesto Spermatogenesis Study Presentation Awarded Presidential Citation at ENDO 2019 Scientific Meeting ENGLEWOOD, CO / ACCESSWIRE / Mar...
Soleno Therapeutics (NASDAQ: SLNO ) -10% . More news on: Soleno Therapeutics, Inc., Tencent Music Entertainment Group, Cellectar Biosciences, Inc., Stocks on the move, Read more ...
Nano cap Aytu BioScience ( AYTU +9.9% ) is up on more than double normal volume on the heels of published data from an open-label Phase 4 study, MY-T , assessing Natesto in hypogonadal males who were either naïve to testosterone treatment or were previously using topical testostero...
Altimmune (NASDAQ: ALT ) +44% on positive NasoVAX data . More news on: Altimmune, Inc., Vaxart, Inc., Cellectar Biosciences, Inc., Stocks on the move, Read more ...
Natesto ''MY-T study'' - First Study to Demonstrate Improvement of Low T Symptoms in Men After Switching to Natesto from Topical Testosterone Gels ENGLEWOOD, CO / ACCESSWIRE / March 19, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global com...
Datato be Presented on Ongoing Natesto Spermatogenesis Study, Study Evaluating theEffect of Natesto Nasal Testosterone on Male Fertility Parameters ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercia...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...